Medtronic PLC $MDT Shares Acquired by Brandywine Global Investment Management LLC

Brandywine Global Investment Management LLC boosted its position in Medtronic PLC (NYSE:MDT) by 4.8% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,239,919 shares of the medical technology company’s stock after acquiring an additional 56,247 shares during the quarter. Medtronic accounts for about 0.8% of Brandywine Global Investment Management LLC’s holdings, making the stock its 28th biggest holding. Brandywine Global Investment Management LLC owned 0.10% of Medtronic worth $108,084,000 at the end of the most recent reporting period.

A number of other institutional investors also recently added to or reduced their stakes in the company. Gilbert & Cook Inc. raised its holdings in shares of Medtronic by 1.9% in the 2nd quarter. Gilbert & Cook Inc. now owns 6,103 shares of the medical technology company’s stock valued at $532,000 after purchasing an additional 114 shares in the last quarter. Red Spruce Capital LLC grew its stake in shares of Medtronic by 0.5% during the second quarter. Red Spruce Capital LLC now owns 23,707 shares of the medical technology company’s stock worth $2,067,000 after purchasing an additional 118 shares in the last quarter. Certior Financial Group LLC increased its holdings in Medtronic by 3.7% in the first quarter. Certior Financial Group LLC now owns 3,450 shares of the medical technology company’s stock valued at $310,000 after buying an additional 122 shares during the last quarter. PrairieView Partners LLC raised its stake in Medtronic by 3.6% in the second quarter. PrairieView Partners LLC now owns 3,726 shares of the medical technology company’s stock valued at $324,000 after buying an additional 128 shares in the last quarter. Finally, Motco lifted its holdings in Medtronic by 27.0% during the 1st quarter. Motco now owns 635 shares of the medical technology company’s stock worth $57,000 after buying an additional 135 shares during the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Insider Activity at Medtronic

In other news, EVP Harry Skip Kiil sold 8,605 shares of the business’s stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. The trade was a 19.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director William R. Jellison purchased 2,500 shares of the business’s stock in a transaction dated Monday, August 25th. The shares were bought at an average price of $92.37 per share, with a total value of $230,925.00. Following the purchase, the director directly owned 5,000 shares of the company’s stock, valued at approximately $461,850. The trade was a 100.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. 0.26% of the stock is owned by corporate insiders.

Medtronic Stock Down 1.0%

Shares of NYSE:MDT opened at $99.36 on Friday. Medtronic PLC has a 1-year low of $79.29 and a 1-year high of $102.59. The company has a debt-to-equity ratio of 0.54, a current ratio of 2.01 and a quick ratio of 1.50. The stock has a market cap of $127.45 billion, a P/E ratio of 27.37, a P/E/G ratio of 2.42 and a beta of 0.77. The firm has a fifty day moving average price of $94.90 and a 200 day moving average price of $90.76.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The business had revenue of $8.96 billion during the quarter, compared to analysts’ expectations of $8.86 billion. During the same period in the prior year, the company earned $1.26 earnings per share. The business’s revenue was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts predict that Medtronic PLC will post 5.46 EPS for the current year.

Analyst Upgrades and Downgrades

MDT has been the subject of several analyst reports. Morgan Stanley upped their price objective on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research report on Wednesday. UBS Group upped their price target on Medtronic from $95.00 to $102.00 and gave the company a “neutral” rating in a report on Wednesday. Wells Fargo & Company increased their price target on shares of Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday. Daiwa Capital Markets boosted their price objective on shares of Medtronic from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. Finally, Barclays upped their target price on shares of Medtronic from $109.00 to $111.00 and gave the company an “overweight” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have assigned a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $109.72.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.